This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    01/01/18

    Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia

    Ibrutinib is the first in-class, orally administered, Bruton's tyrosine kinase (BTK) inhibitor that abrogates the critical signaling downstream of the B-cell receptor (BCR).

    • Source: Therapeutic Advances in Hematology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/05/16

    FDA approves label update for Imbruvica (ibrutinib) in chronic lymphocytic leukemia/small lymphocytic lymphoma- Janssen

    The FDA has approved an expansion to the U.S. Prescribing Information (PI) for Imbruvica (ibrutinib), from Janssen, based on data...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/03/16

    FDA approves Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)- AbbVie + Janssen Biotech

    AbbVie announced that the FDA has approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL)....

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    30/10/18

    NICE does not recommend Venclyxto for use with Chronic Lymphocytic Leukaemia.- AbbVie + Roche.

    The National Institution for Health and Care Excellence (NICE) has in its second draft guidance rejected Venclyxto (venetoclax) from AbbVie/Roche...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    23/02/22

    FDA accepts sNDA for Brukinsa to treat chronic lymphocytic leukemia/small lymphocytic leukemia.

    BeiGene announced that the FDA has accepted a supplemental new drug application (sNDA) for Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    Interim analysis of the phase III ALPINE trial comparing Brukinsa to ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma to be reported at EHA 2021 virtual congress.-BeiGene

    BeiGene, Ltd. announced that results from the interim analysis of the Phase III ALPINE trial comparing Brukinsa (zanubrutinib) to ibrutinib (Imbruvica) in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) will be reported in an oral presentation as part of the Presidential Symposium at the 26th European Hematology Association 2021 (EHA2021) Virtual Congress.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    06/06/16

    Phase III follow up data on Imbruvica (ibrutinib) shows efficacy in chronic lymphocytic leukemia and small lymphocytic lymphoma- AbbVie

    AbbVie has announced longer-term follow-up results from Phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    17/02/17

    NICE rejects Venclexta (venetoclax) as a treatment for chronic lymphocytic leukemia.- AbbVie + Roche

    The National Institution for Health and Care Excellence (NICE) has in its first draft guidance rejected Venclexta (venetoclax) from AbbVie...

    Journals
    Journal
    02/04/19

    Chronic lymphocytic leukaemia: the role of T cells in a B cell disease

    Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any)...

    • Source: British Journal of Haematology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    14/09/15

    Supplemental NDA for Imbruvica (ibrutinib) in front line treatment of chronic lymphocytic leukemia submitted to FDA- Janssen Biotech

    A supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib), from Janssen Biotech, has been submitted to the FDA for front-line...

    See more